▲ +1,100.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Mateon Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 1,100.00% upside from the last price of $0.25.
The current consensus among 1 contributing investment analysts is to buy stock in Mateon Therapeutics. This rating has held steady since April 2020, when it changed from a Hold consensus rating.
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.